• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Agenus Brain Cancer Vaccine Doubles Survival

Article

Agenus Inc

said its experimental cancer vaccine helped brain tumor patients live nearly twice as long compared with those who received standard of care treatment.

The drug, when given in addition to standard treatment, extended median overall survival in 50 percent of newly-diagnosed glioblastoma multiforme (GBM) patients to two years in a mid-stage study.

Usually GBM patients succumb to the disease in one year.

Original report:

http://reut.rs/1iQJtLu

Source: Reuters

Related Videos
Joshua K. Sabari, MD
Nicoletta Colombo, MD, PhD
Dr Brian Mulherin
Dr Brian Koffman
Dr Brian Mulherin
Dr Vivek Subbiah
Dr Scott Soefje
Dr Scott Soefje
Dr Mark Fendrick
Related Content
© 2025 MJH Life Sciences
AJMC®
All rights reserved.